Adjunctive Phosphodiesterase-4 Inhibitor Therapy Improves Antibiotic Response to Pulmonary Tuberculosis in a Rabbit Model

EBioMedicine

Volumn 4, Issue , 2016, Pages 104-114

  Subbian, Selvakumar ^a   Tsenova, Liana ^a   Holloway, Jennifer ^b   Peixoto, Blas ^a   O'Brien, Paul ^a   Dartois, Véronique ^a   Khetani, Vikram ^c   Zeldis, Jerome B ^c   Kaplan, Gilla ^a,d  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c CELGENE CORPORATION   (United States)

^d BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

Immune modulation; Inflammation; Lung fibrosis; Phosphodiesterase inhibitor; Pulmonary tuberculosis

Indexed keywords

CC 11050; ISONIAZID; PHOSPHODIESTERASE IV INHIBITOR; TRANSCRIPTOME; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; DRUG COMBINATION; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL LOAD; BACTERIUM CULTURE; CELL PROLIFERATION; CHRONIC INFLAMMATION; CLINICAL OUTCOME; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE SEVERITY; DNA TRANSCRIPTION; DRUG STRUCTURE; FIBROSIS; FLOW CYTOMETRY; GENE EXPRESSION; HISTOLOGY; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; LUNG TUBERCULOSIS; MACROPHAGE ACTIVATION; MICROARRAY ANALYSIS; MORPHOMETRY; MULTIPLE REACTION MONITORING; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RABBIT MODEL; RNA ISOLATION; SINGLE DRUG DOSE; T LYMPHOCYTE; ANIMAL; DRUG COMBINATION; DRUG POTENTIATION; FEMALE; RABBITS AND HARES; TUBERCULOSIS, PULMONARY;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG COMBINATIONS; DRUG SYNERGISM; FEMALE; ISONIAZID; PHOSPHODIESTERASE 4 INHIBITORS; RABBITS; TUBERCULOSIS, PULMONARY;

EID: 84955164158     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.01.015     Document Type: Article

References (52)

1. Mitchison, D.A., Role of individual drugs in the chemotherapy of tuberculosis. Int J. Tuberc. Lung Dis. 4 (2000), 796–806.
2. Sirgel, F.A., Donald, P.R., Odhiambo, J., Githui, W., Umapathy, K.C., et al. A multicentre study of the early bactericidal Activity of anti-tuberculosis drugs. J. Antimicrob. Chemother. 45 (2000), 859–870.
3. Zhang, Y., Yew, W.W., Barer, M.R., Targeting persisters for tuberculosis control. Antimicrob. Agents Chemother. 56 (2012), 2223–2230.
4. Cardona, P.J., Revisiting the natural history of tuberculosis. The inclusion of constant reinfection, host tolerance, and damage-response frameworks leads to a better understanding of latent infection and its evolution towards active disease. Arch. Immunol. Ther. Exp. 58 (2010), 7–14.
5. Ehlers, S., Lazy, dynamic or minimally recrudescent? On the elusive nature and location of the Mycobacterium responsible for latent tuberculosis. Infection 37 (2009), 87–95.
6. den Boon, S., Verver, S., Lombard, C.J., Bateman, E.D., Irusen, E.M., et al. Comparison of symptoms and treatment outcomes between actively and passively detected tuberculosis cases: the additional Value of active case finding. Epidemiol. Infect. 136 (2008), 1342–1349.
7. Verver, S., Warren, R.M., Beyers, N., Richardson, M., van der Spuy, G.D., et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am. J. Respir. Crit. Care Med. 171 (2005), 1430–1435.
8. Zumla, A.I., Gillespie, S.H., Hoelscher, M., Philips, P.P., Cole, S.T., et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect. Dis. 14 (2014), 327–340.
9. Dorhoi, A., Kaufmann, S.H., Perspectives on host adaptation in response to Mycobacterium tuberculosis: modulation of inflammation. Semin. Immunol. 26 (2014), 533–542.
10. Behar, S.M., Carpenter, S.M., Booty, M.G., Barber, D.L., Jayaraman, P., Orchestration of pulmonary T cell immunity during Mycobacterium tuberculosis infection: immunity interruptus. Semin. Immunol. 26 (2014), 559–577.
11. Kaufmann, S.H., Dorhoi, A., Inflammation in tuberculosis: interactions, imbalances and interventions. Curr. Opin. Immunol. 25 (2013), 441–449.
12. Sugawara, I., Why does tuberculosis lead to specific inflammation?. Nihon Hansenbyo Gakkai Zasshi 78 (2009), 263–269.
13. Schlesinger, L.S., Role of mononuclear phagocytes in M. tuberculosis pathogenesis. J. Investig. Med. 44 (1996), 312–323.
14. Chao, M.C., Rubin, E.J., Letting sleeping dos lie: does dormancy play a role in tuberculosis?. Annu. Rev. Microbiol. 64 (2010), 293–311.
15. Wallis, R.S., Hafner, R., Advancing host-directed therapy for tuberculosis. Nat. Rev. Immunol. 15 (2015), 255–263.
16. Hawn, T.R., Shah, J.A., Kalman, D., New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics. Immunol. Rev. 264 (2015), 344–362.
17. Francis, S.H., Blount, M.A., Corbin, J.D., Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol. Rev. 91 (2011), 651–690.
18. Conti, M., Richter, W., Mehats, C., Livera, G., Park, J.Y., et al. Cyclic AMP-specific PDE4 phosphodiesterases as critical Components of cyclic AMP signaling. J. Biol. Chem. 278 (2003), 5493–5496.
19. Keravis, T., Lugnier, C., Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br. J. Pharmacol. 165 (2012), 1288–1305.
20. Bender, A.T., Beavo, J.A., Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 58 (2006), 488–520.
21. Spina, D., Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs 63 (2003), 2575–2594.
22. Houslay, M.D., Sullivan, M., Bolger, G.B., The multienzyme pde4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv. Pharmacol. 44 (1998), 225–342.
23. Azam, M.A., Tripuraneni, N.S., Selective phosphodiesterase 4B inhibitors: a review. Sci. Pharm. 82 (2014), 453–481.
24. Maurice, D.H., Ke, H., Ahmad, F., Wang, Y., Chung, J., et al. Advances in targeting cyclic nucleotide phosphodiesterases. Nat. Rev. Drug Discov. 13 (2014), 290–314.
25. Moreira, A.L., Tsenova-Berkova, L., Wang, J., Laochumroonvorapong, P., Freeman, S., et al. Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis. Tuber. Lung Dis. 78 (1997), 47–55.
26. Tsenova, L., Mangaliso, B., Muller, G., Chen, Y., Freedman, V.H., et al. Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis. Antimicrob. Agents Chemother. 46 (2002), 1887–1895.
27. Koo, M.S., Manca, C., Yang, G., O'Brien, P., Sung, N., et al. Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice. PLoS One, 6, 2011, e17091.
28. Subbian, S., Tsenova, L., O'Brien, P., Yang, G., Koo, M.S., et al. Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog., 7, 2011, e1002262.
29. Subbian, S., Tsenova, L., O'Brien, P., Yang, G., Koo, M.S., et al. Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology. Am. J. Pathol. 179 (2011), 289–301.
30. Subbian, S., Tsenova, L., Yang, G., O'Brien, P., Parsons, S., et al. Chronic pulmonary cavitary tuberculosis in rabbits: a failed host immune response. Open Biol., 1, 2011, 110016.
31. Tsenova, L.H.R., Ellison, E., Manca, C., Kaplan, G., Aerosol exposure system for rabbits: application to M. tuberculosis infection. Appl. Biosaf. 11 (2006), 7–14.
32. Subbian, S., Tsenova, L., O'Brien, P., Yang, G., Kushner, N.L., et al. Spontaneous latency in a rabbit model of pulmonary tuberculosis. Am. J. Pathol. 181 (2012), 1711–1724.
33. Hubner, R.H., Gitter, W., El Mokhtari, N.E., Mathiak, M., Both, M., et al. Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques 44:507–511 (2008), 507–514.
34. Robbe, A., Tassin, A., Carpentier, J., Decleves, A.E., Mekinda Ngono, Z.L., et al. Intratracheal bleomycin aerosolization: the best route of administration for a scalable and homogeneous pulmonary fibrosis rat model?. Biomed. Res. Int., 2015, 2015, 198418.
35. Subbian, S., O'Brien, P., Kushner, N.L., Yang, G., Tsenova, L., et al. Molecular immunologic correlates of spontaneous latency in a rabbit model of pulmonary tuberculosis. Cell Commun. Signal., 11, 2013, 16.
36. Subbian, S., Bandyopadhyay, N., Tsenova, L., O'Brien, P., Khetani, V., et al. Early innate immunity determines outcome of Mycobacterium tuberculosis pulmonary infection in rabbits. Cell Commun. Signal., 11, 2013, 60.
37. Maiga, M., Ammerman, N.C., Maiga, M.C., Tounkara, A., Siddiqui, S., et al. Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment. J. Infect. Dis. 208 (2013), 512–519.
38. Houslay, M.D., Adams, D.R., PDE4 cAMP Phosphodiesterases: Modular Enzymes That Orchestrate Signalling Cross-Talk, Desensitization and Compartmentalization. Biochem. J. 370 (2003), 1–18.
39. MacKenzie, S.J., Houslay, M.D., Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells. Biochem. J. 347 (2000), 571–578.
40. Gupta, U.D., Katoch, V.M., Animal Models of Tuberculosis. Tuberculosis (Edinb.) 85 (2005), 277–293.
41. O'Toole, R., Experimental models used to study human tuberculosis. Adv. Appl. Microbiol. 71 (2010), 75–89.
42. Kaplan, G., Post, F.A., Moreira, A.L., Wainwright, H., Kreiswirth, B.N., et al. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect. Immun. 71 (2003), 7099–7108.
43. Subbian, S., Tsenova, L., Kim, M.J., Wainwright, H.C., Visser, A., et al. Lesion-specific immune response in granulomas of patients with pulmonary tuberculosis: a pilot study. PLoS One, 10, 2015, e0132249.
44. Hunter, R.L., On the pathogenesis of post primary tuberculosis: the role of bronchial obstruction in the pathogenesis of cavities. Tuberculosis (Edinb.) 91:Suppl. 1 (2011), S6–S10.
45. Hunter, R.L., Pathology of post primary tuberculosis of the lung: an illustrated critical review. Tuberculosis (Edinb.) 91 (2011), 497–509.
46. Kjellsson, M.C., Via, L.E., Goh, A., Weiner, D., Low, K.M., et al. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob. Agents Chemother. 56 (2012), 446–457.
47. Paige, C., Bishai, W.R., Penitentiary or penthouse condo: the tuberculous granuloma from the microbe's point of view. Cell. Microbiol. 12 (2010), 301–309.
48. Ong, C.W., Elkington, P.T., Friedland, J.S., Tuberculosis, pulmonary cavitation, and matrix metalloproteinases. Am. J. Respir. Crit. Care Med. 190 (2014), 9–18.
49. Elkington, P., Shiomi, T., Breen, R., Nuttall, R.K., Ugarte-Gil, C.A., et al. MMP-1 drives immunopathology in human tuberculosis and transgenic mice. J. Clin. Invest. 121 (2011), 1827–1833.
50. Dharmadhikari, A.S., Nardell, E.A., What animal models teach humans about tuberculosis. Am. J. Respir. Cell Mol. Biol. 39 (2008), 503–508.
51. Kim, M.J., Wainwright, H.C., Locketz, M., Bekker, L.G., Walther, G.B., et al. Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. EMBO Mol. Med. 2 (2010), 258–274.
52. Mehra, S., Pahar, B., Dutta, N.K., Conerly, C.N., Philippi-Falkenstein, K., et al. Transcriptional reprogramming in nonhuman primate (rhesus macaque) tuberculosis granulomas. PLoS One, 5, 2010, e12266.